30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q14 Revenue: Anika Therapeutics

$11.5MM, +3% (MONOVISC ~$1.7MM)

  • Marked 1st commercial sale of MONOVISC in U.S., not yet seeing cannibalization of ORTHOVISC
  • Seeks to complete clinical trial and submit CE Mark application by end of 2014 for Cingal HA+ steroid injection
  • Planning U.S. U.S. clinical trial to support FDA submission for Hyalofast 1-step cartilage repair solution